Regimen Reference Order – LYMP – R-ICE (Split Day SLOW IV riTUXimab)

ARIA: LYMP – [R-ICE (Split Day SLOW)]

Planned Course:Every 21 days up to 6 cyclesIndication for Use:Relapsed/Refractory Non-Hodgkin Lymphoma

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than 1×10^{9} /L AND Platelets equal to or greater than 75×10^{9} /L

Contact Hematologist if parameters not met

Note: Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements		
Drug	Dose	CCMB Administration Guideline
Instruct patient to st (Self-administered a		vdration (600-900 mL) the morning of ifosfamide treatment
allopurinol	300 mg	Orally once daily for 10 days to begin 3 days prior to Cycle 1 (Self-administered at home)
		Only patients at risk of tumor lysis syndrome will be prescribed allopurinol
		Note: allopurinol should not be prescribed beyond 10 days unless under the direction of the hematologist. See Additional Information

Treatment Regimen – LYMP – R-ICE (Split Day SLOW IV riTUXimab)

Establish primary solution 500 mL of: normal saline		
Drug	Dose	CCMB Administration Guideline
Day 1		
cetirizine	10 mg	Orally 30 minutes prior to riTUXimab
acetaminophen	650 mg	Orally 30 minutes prior to riTUXimab
dexamethasone	12 to 20 mg 20 mg for Cycle 1	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after c	ompletion of IV pre-me	dication(s) before starting riTUXimab
riTUXimab (IV brand name specific)		



*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order *Alert: Pharmacy to ensure final volume on label
OR
Slow infusion (if equal to or less than 6 months since last riTUXimab dose): IV made up to a final concentration of 1 mg/mL in normal saline. Start at 100 mg/hr for 30 minutes and escalate infusion rate in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr
*Nursing Alert: IV tubing is primed with riTUXimab *Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order *Alert: Pharmacy to ensure final volume on label

Day 2

Day Z			
Drug	Hours of Administration	Dose	CCMB Administration Guideline
normal saline	minus 1 hour and 15 minutes	500 mL	IV over 1 hour (Pre hydration)
ondansetron	minus 30 minutes	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	minus 30 minutes	12 mg	Orally 30 minutes pre-chemotherapy
mesna	minus 15 minutes	333 mg/m ²	IV in normal saline 50 mL over 15 minutes Immediately prior to ifosfamide
ifosfamide	Hour 0	1667 mg/m ²	IV in normal saline 250 mL over 1 hour
CARBOplatin	Hour 1	AUC 5 mg/mL.min; maximum dose 750 mg (see table below)	IV in D5W 250 mL over 30 minutes
etoposide	Hour 1 and 30 minutes	100 mg/m ²	IV in normal saline 500 mL over 1 hour Use non-DEHP bags and non-DEHP administration sets
normal saline	Hour 2 and 30 minutes	500 mL	IV over 90 minutes (Post hydration)
mesna	Hour 4	333 mg/m ²	IV in normal saline 50 mL over 15 minutes
mesna	Hour 6	666 mg/m ²	Orally with juice or soft drink (Self-administered at home) *Nursing Alert: Inform patient time to take dose
Days 3 and 4			
normal saline	minus 1 hour and 15 minutes	500 mL	IV over 1 hour (Pre hydration)



Drug	Hours of Administration	Dose	CCMB Administration Guideline
ondansetron	minus 30 minutes	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	minus 30 minutes	12 mg	Orally 30 minutes pre-chemotherapy
mesna	minus 15 minutes	333 mg/m ²	IV in normal saline 50 mL over 15 minutes Immediately prior to ifosfamide
ifosfamide	Hour 0	1667 mg/m ²	IV in normal saline 250 mL over 1 hour *Alert: start of ifosfamide infusion will be considered "Hour 0"
etoposide	Hour 1	100 mg/m ²	IV in normal saline 500 mL over 1 hour Use non-DEHP bags and non-DEHP administration sets
normal saline	Hour 2	500 mL	IV over 2 hours (Post hydration)
mesna	Hour 4	333 mg/m ²	IV in normal saline 50 mL over 15 minutes
mesna	Hour 6	666 mg/m ²	Orally with juice or soft drink (Self-administered at home) *Nursing Alert: Inform patient time to take dose

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Hepatitis B serology

• Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

All Cycles

• CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders

All doses (riTUXimab)

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not



Recommended Support Medications			
Drug	Dose	CCMB Administration Guideline	
pegfilgrastim (brand name specific)	6 mg	Subcutaneous once on Day 6 *Alert: pegfilgrastim to be given as a single dose once per chemotherapy cycle no sooner than 24 hours after chemotherapy	
dexamethasone	8 mg	Orally once daily on Days 5 and 6	
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting	


DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Ensure patient receives pegfilgrastim supply if patient is self-administering at home
- Instruct patient to:
 - Self-administer "Hour 6" of mesna by mixing the contents of the mesna syringe in juice (not grapefruit) or 0 soft drink. If patient vomits within 2 hours of taking "Hour 6" mesna, they should be advised to contact their cancer team. Patient may require intravenous hydration
 - Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit 0
 - Continue taking anti-emetic(s) at home 0
 - Report changes in mental status; ifosfamide can cause encephalopathy (rare) 0
 - Maintain oral intake of 2000 mL (8 glasses) of fluid daily at home 0
 - Empty bladder every 2 hours while awake and at bedtime for 24 hours after each dose of ifosfamide 0
 - Obtain immediate assistance as per your clinic's contact instructions if: 0
 - Symptoms of hemorrhagic cystitis (e.g. dysuria, hematuria)
 - Unable to drink recommended amount of fluid
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to • CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients for ordering and interpreting HBV serology and prescribing antiviral prophylaxis
- Unless patient was taking allopurinol for gout or other reasons unrelated to the patient's underlying lymphoma, allopurinol should not be prescribed with cycle 2 and onwards unless directed by hematologist
- Administering nurse must document any infusion-related reactions with any dose of riTUXimab
- Intravenous riTUXimab formulation is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after riTUXimab. Ensure prescription label matches the brand name on prescribed order for intravenous riTUXimab
- CARBOplatin dose considerations:
 - CCMB Lymphoproliferative DSG uses actual body weight to calculate GFR
 - CCMB Lymphoproliferative DSG uses a maximum CARBOplatin dose of 750 mg for this regimen 0
 - If calculated CARBOplatin dose differs more than 10% from prescribed CARBOplatin dose, contact the 0 prescriber





AUC= Area Under Curve

The estimated creatinine clearance is based on limited evidence. Sound clinical judgment and interpretation of the estimation are required, because the equation above may not be appropriate for some patient populations (for example, acute renal failure).

